• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Medical Marijuana for Chronic Pain: The Cart Before the Horse?

Medical Marijuana for Chronic Pain: The Cart Before the Horse?

February 3, 2021
Alison Knopf
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Alison Knopf Editor, Alcoholism & Drug Abuse Weekly. Ms. Knopf has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In 2019, 17.5% of the American population used cannabis in the past year—up from 11.0% in 2002 (www.samhsa.gov/data/release/2019-national-survey-drug-use-and-health-nsduh-releases). As more states legalize cannabis for medical or recreational use, it’s becoming more common for our patients to add medical marijuana to their medication regimen for various purported indications. In this primer, we will synthesize the debate surrounding the use of medical marijuana for a variety of syndromes, with a focus on pain.

Just to review some basics, cannabinoids can be classified into three groups, according to the National Institute on Drug Abuse:

  • Phytocannabinoids: naturally occurring, derived from flora (eg, THC, CBD)

  • Endocannabinoids: produced endo­genously (eg, anandamide, 2-AG)

  • Synthetic cannabinoids: created artificially (eg, dronabinol, nabilone)


Of the hundreds of cannabinoids that have been isolated and identified, the most commonly known are the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the psychoactive component of cannabis.

Medical uses approved by agencies
There are currently only a handful of medical conditions for which cannabis products have been approved by federal agencies in the US and Canada: AIDS-related anorexia, chemotherapy-induced nausea, seizures, and multiple sclerosis. Here are the specifics of these products and indications:

  • Dronabinol (Marinol capsules and Syndros oral solution): This synthetic form of THC is approved for the treatment of refractory chemotherapy-associated nausea and vomiting, as well as anorexia associated with weight loss in patients with AIDS.

  • Cannabidiol (Epidiolex): This synthetic form of CBD is approved for the treatment of three rare and severe forms of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.


Additionally, Sativex (a combination of plant-derived THC and CBD in slightly more than a 1:1 ratio) is approved in Canada and Europe for the treatment of neuropathic symptoms associated with multiple sclerosis, but it is not yet FDA approved or available in the US.

Treatment of non-cancer pain
Cannabis may be effective for treating chronic non-cancer pain. In 2017, the National Academies of Sciences, Engineering, and Medicine concluded that there is “evidence to support that patients who were treated with cannabis or cannabinoids were more likely to experience a significant reduction in pain symptoms,” adding that there was “substantial evidence” that short-term use of man-made oral cannabinoids improves multiple sclerosis–related muscle spasms (www.tinyurl.com/j9nr9vy).

Treatment of opioid use disorder
Observational studies have suggested that where medical marijuana is legal, there is less opioid prescribing—though these are correlational data and do not necessarily imply that legalizing marijuana causes less opioid use. The correlational evidence of the association between cannabis legalization and overdose reductions is clear from several studies (Bachhuber MA et al, JAMA Internal Medicine 2014;174(10):1668–1673). However, there is also evidence that cannabis use increases the risk of developing opioid use disorder (Olfson M et al, Am J Psychiatry 2018;175(1):47–53).

American Society of Addiction Medicine (ASAM) policy statement
According to a policy statement from ASAM released in October 2020, there is a “lack of sufficient scientific evidence” for the effectiveness of cannabis as a medication for many indications approved by states (www.tinyurl.com/y5nx4wt7). ASAM emphasizes the association between using cannabis and the onset of psychiatric disorders, especially psychosis.

Side effects
When working with patients who use marijuana recreationally or for treatment of symptoms, clinicians should be aware of potential adverse effects. We spoke with Benjamin Caplan, MD, a physician with a specialty in treating chronic pain. “I warn patients of a variety of potential side effects, including light-headedness, upset stomach, and occasional strong urges to rest or seclude oneself from outside stimulation,” said Caplan. “It’s not uncommon for cannabis to bring about novel, often pleasant physical sensations, like extreme muscle relaxation, or interesting thought patterns, such as distracted thinking or wildly creative thought, that occur with some of the cannabis varieties.”

As for panic attacks, these usually occur when patients have mistakenly taken too high a dose. This is often because the patient is using an old product that has resettled, with all of the active ingredients at the bottom. Once they shake the bottle, they are usually OK.

One reality: Insurance doesn’t pay for medical marijuana. In some places it does help cover physician visits, said Caplan. In Massachusetts, the dispensaries pay back the cost of the medical visits in free product credits, he said.

NIH and research
The National Institutes of Health (NIH) have started providing formal grants for preclinical and basic researchers to start doing studies on medical cannabis, said Mikhail Kogan, MD, medical director of the George Washington Center for Integrative Medicine and associate professor of medicine at George Washington University. Kogan has treated more than 3,000 patients with cannabis. “Some of the studies involve synthetics, but there’s also beginning to be research in botanicals,” Kogan told Carlat.

The difference between cannabis and dronabinol (synthetic THC) is that cannabis can be more easily titrated, starting with a subtherapeutic dose. Clinicians know that this dose won’t relieve the pain immediately, but at least the side effects are minimal. After waiting a few days, once the side effects decrease and the body adjusts, the dose can be increased. Clinicians will know they’ve arrived at the right dose when there is efficacy and no side effects.

Kogan’s interest in cannabis for pain stems from the fact that his practice is mainly geriatric and palliative (although he tends to use opioids, not cannabis, in palliative care). “In geriatrics, I use cannabis as first-line treatment for a number of conditions.” He also likes cannabis because it is less toxic than ibuprofen or acetaminophen. It also treats many problems that co-occur, especially in older adults. “I can use one plant for chronic pain, insomnia, anxiety, and nausea,” said Kogan. “And I feel strongly that older adults should be the first target” for medical cannabis.

CATR Verdict: Cannabis, while still illegal in the federal arena even for medical use, is legal in many states for medical and recreational use. Physicians may increasingly work with patients using medical marijuana to manage symptoms, and should be aware of formulations, patterns of use, and adverse effects. While some data support the use of cannabis for various conditions, the data are limited regarding its use in chronic conditions such as pain or substance use disorders, and most medical societies agree that more data are needed prior to recommending it for such conditions. For additional resources, see: www.fsmb.org/siteassets/advocacy/policies/model-guidelines-for-the-recommendation-of-marijuana-in-patient-care.pdf; www.cedclinic.com
Addiction Treatment
KEYWORDS clinical-practice harm-reduction marijuana pain
    Alison Knopf

    Addiction and Family: What You Need to Know

    More from this author
    www.thecarlatreport.com
    Issue Date: February 3, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Pain and Addiction, CATR, January/February 2021
    Kratom: A Primer
    Supporting Patients With Pain and Addiction
    Medical Marijuana for Chronic Pain: The Cart Before the Horse?
    Medical Cannabis for Chronic Pain and Quality of Life
    Do We Need to Be Face-to-Face to Treat Alcohol Use Disorder?
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.